Cobimetinib impairs tumor survival and immune escape by altering my-CAFs in BRAFV600E-mutated anaplastic thyroid carcinoma
4 affiliations
- 1Institute of Pathology, Section Immunopathology, Martin Luther University Halle-Wittenberg
- 2Institute of Tumor Immunology, Martin Luther University Halle-Wittenberg
- 3Department of Visceral, Vascular and Endocrine Surgery, Martin Luther University Halle-Wittenberg
- 4Department of Hematology/Oncology and Stem Cell Transplantation, KIM IV, Martin-Luther University Halle-Wittenberg
Abstract
Anaplastic thyroid carcinoma is one of the most aggressive thyroid cancers characterized by rapid progression and high resistance to conventional therapies. Although mutations in the BRAF gene are common in thyroid cancer, targeted therapies against this mutation show limited clinical benefit. This study investigated whether inhibition of downstream signaling pathways using the selected MEK inhibitor cobimetinib provides advantages over direct BRAF inhibition. Genomic and expression analyses of thyroid cancer datasets confirmed frequent BRAF alterations and activation of MAPK-pathway-associated signaling. Functional studies using thyroid cancer cell lines demonstrated that cobimetinib more effectively reduced MAPK pathway activity specifically reducing ERK1/2 phosphorylation compared to direct BRAF inhibition. This pathway suppression was associated with decreased tumor cell invasion, migration, and expression of epithelial–mesenchymal transition markers, alongside increased induction of late apoptosis. Furthermore, cobimetinib altered immune-related features of tumor cells by reducing expression of immune inhibitory molecules and cytokine secretion, while simultaneously enhancing expression of molecules involved in antigen presentation, such as HLA-ABC. Co-culture experiments with human fibroblasts showed that cobimetinib modulates tumor–fibroblast communication and fibroblast phenotype composition. Cobimetinib reduced the formation of specific immune-suppressive fibroblast subtypes, whereas exposure to interleukin-8 promoted their development and increased tumor cell migration. Secretome profiling confirmed that cobimetinib markedly depleted pro-tumorigenic cytokines, particularly reducing IL-8 secretion. While data provide preclinical evidence that downstream MEK inhibition alters tumor cell signaling and IL-8-associated tumor–fibroblast communication in ATC-centered models, they do not establish cobimetinib monotherapy as a replacement for clinically established BRAF/MEK combination therapies. Instead, these data support the broader therapeutic potential of MEK inhibitors as a strategy to target both tumor progression and immune evasion in aggressive endocrine malignancies.
Related
- Conditional survival and dynamic prognostic nomogram for histologically defined anaplastic ganglioglioma: a SEER-based analysis
- Efficacy and safety of dabrafenib plus trametinib in BRAFV600E-mutated advanced thyroid carcinoma: Real world experience in 37 patients
- Statement of Retraction: Long noncoding RNA MALAT1 knockdown inhibits progression of anaplastic thyroid carcinoma by regulating miR-200a-3p/FOXA1.
- Embryonic reprogramming drives anaplastic transformation in thyroid carcinoma
- Exophytic Papillary Thyroid Carcinoma With Anaplastic Transformation in a Cervical Lymph Node: A Case Report and Review of the Literature.
BibTeX
@article{udinotti2026cobimetinib,
title = {{Cobimetinib impairs tumor survival and immune escape by altering my-CAFs in BRAFV600E-mutated anaplastic thyroid carcinoma}},
author = {Mario Udinotti and Niclas Ramm and Thamer Abed Alhaleem Amin Hamdan and Muhammad Sameer Ali Khan and Udo Siebolts and Marcus Bauer and Kerstin Lorenz and Christine Dierks and Claudia Wickenhauser and Barbara Seliger},
journal = {Experimental Hematology \& Oncology},
year = {2026},
month = oct,
doi = {10.1186/s40164-026-00839-4},
url = {https://doi.org/10.1186/s40164-026-00839-4},
note = {CC BY},
}
RIS
TY - JOUR
TI - Cobimetinib impairs tumor survival and immune escape by altering my-CAFs in BRAFV600E-mutated anaplastic thyroid carcinoma
AU - Mario Udinotti
AU - Niclas Ramm
AU - Thamer Abed Alhaleem Amin Hamdan
AU - Muhammad Sameer Ali Khan
AU - Udo Siebolts
AU - Marcus Bauer
AU - Kerstin Lorenz
AU - Christine Dierks
AU - Claudia Wickenhauser
AU - Barbara Seliger
PY - 2026
DA - 2026/10/25
JO - Experimental Hematology & Oncology
DO - 10.1186/s40164-026-00839-4
UR - https://doi.org/10.1186/s40164-026-00839-4
AB - Anaplastic thyroid carcinoma is one of the most aggressive thyroid cancers characterized by rapid progression and high resistance to conventional therapies. Although mutations in the BRAF gene are common in thyroid cancer, targeted therapies against this mutation show limited clinical benefit. This study investigated whether inhibition of downstream signaling pathways using the selected MEK inhibitor cobimetinib provides advantages over direct BRAF inhibition. Genomic and expression analyses of thyroid cancer datasets confirmed frequent BRAF alterations and activation of MAPK-pathway-associated signaling. Functional studies using thyroid cancer cell lines demonstrated that cobimetinib more effectively reduced MAPK pathway activity specifically reducing ERK1/2 phosphorylation compared to direct BRAF inhibition. This pathway suppression was associated with decreased tumor cell invasion, migration, and expression of epithelial–mesenchymal transition markers, alongside increased induction of late apoptosis. Furthermore, cobimetinib altered immune-related features of tumor cells by reducing expression of immune inhibitory molecules and cytokine secretion, while simultaneously enhancing expression of molecules involved in antigen presentation, such as HLA-ABC. Co-culture experiments with human fibroblasts showed that cobimetinib modulates tumor–fibroblast communication and fibroblast phenotype composition. Cobimetinib reduced the formation of specific immune-suppressive fibroblast subtypes, whereas exposure to interleukin-8 promoted their development and increased tumor cell migration. Secretome profiling confirmed that cobimetinib markedly depleted pro-tumorigenic cytokines, particularly reducing IL-8 secretion. While data provide preclinical evidence that downstream MEK inhibition alters tumor cell signaling and IL-8-associated tumor–fibroblast communication in ATC-centered models, they do not establish cobimetinib monotherapy as a replacement for clinically established BRAF/MEK combination therapies. Instead, these data support the broader therapeutic potential of MEK inhibitors as a strategy to target both tumor progression and immune evasion in aggressive endocrine malignancies.
SN - 2162-3619
ER -